Imaging Properties and Tumor Targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
暂无分享,去创建一个
H. Tilg | P. Hohenberger | W. Jaschke | C. Decristoforo | I. Virgolini | F. Orlandi | C. Uprimny | C. Manzl | L. Gruber | Maria Theresia Kasseroler | M. Mariani | S. Schoenberg | B. Zelger
[1] S. Schoenberg,et al. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients , 2020, The Journal of Nuclear Medicine.
[2] V. Tolmachev,et al. Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26 , 2019, International journal of cancer.
[3] E. Krenning,et al. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results , 2017, The Journal of Nuclear Medicine.
[4] E. Wardelmann,et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] K. Søreide,et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.
[6] T. Taguchi,et al. Targeting Gastrointestinal Stromal Tumor with 68Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines. , 2016, Cancer biotherapy & radiopharmaceuticals.
[7] H. Joensuu,et al. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. , 2015, European journal of cancer.
[8] W. Hohenberger,et al. Management of liver metastases of gastrointestinal stromal tumors (GIST). , 2015, Annals of hepatology.
[9] R. Maki,et al. GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Zhongqiang Zhang,et al. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials , 2014, Drug design, development and therapy.
[11] N. Avril,et al. GRP Receptor Imaging of Prostate Cancer Using [99mTc]Demobesin 4: a First-in-Man Study , 2014, Molecular Imaging and Biology.
[12] F. van Coevorden,et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] C. Fletcher. The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.
[14] S. Rosati,et al. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study. , 2013, Nuclear medicine and biology.
[15] I. Jambor,et al. In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.
[16] I. Jambor,et al. Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men , 2013, The Journal of Nuclear Medicine.
[17] L. Strauss,et al. Correlation of the Ga-68-Bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas as Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays , 2011, Molecular Imaging and Biology.
[18] Kirsten Schmieder,et al. Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results , 2011, Clinical nuclear medicine.
[19] W. Schima,et al. Bildgebende Diagnostik bei GIST , 2009, Wiener Medizinische Wochenschrift.
[20] J. Lasota,et al. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.
[21] C. Santos-Cuevas,et al. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women , 2008, Nuclear medicine communications.
[22] Haesun Choi,et al. Response evaluation of gastrointestinal stromal tumors. , 2008, The oncologist.
[23] P. Woll,et al. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate , 2008, Therapeutics and clinical risk management.
[24] Peter Hohenberger,et al. 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.
[25] C. Charnsangavej,et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.
[26] L. Mazzucchelli,et al. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[27] S. Hirota,et al. Gastrointestinal stromal tumors (GIST): A model for molecule‐based diagnosis and treatment of solid tumors , 2003, Cancer science.
[28] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.